Bill Commons

HI SB 2751

died on adjournment

RELATING TO WORKERS' COMPENSATION.

Hawaii · 2026 Regular Session · upper

Follow this bill’s action updates (Atom)

Subscribe in a feed reader. The feed covers recorded actions from the last 30 days; Bill Commons may record an action after it happened at the legislature.

Quick answers

Did HI SB 2751 pass?

No. HI SB 2751 died when the 2026 Regular Session adjourned without final action on it. Bills that die this way are sometimes reintroduced in a later session. Latest recorded action (2026-03-03): The committee on JDC deferred the measure.

What is HI SB 2751 about?

Defines compounded prescription drugs for the purposes of the State's Workers' Compensation Law. Limits dispensing of prescription drugs by physician to 30 days after the industrial injury and requires all prescription drugs to be obtained through the employer's pharmacy benefit manager thereafter. Requires prescription drugs not approved by the Food and Drug Administration (FDA), such as compounds, to be identified as compounds when listed on the treatment plan and when billed, and be supported by a statement of medical necessity documenting the case of medical need for a compound drug over an FDA-approved over-the-counter or prescription drug of similar therapeutic effect. Effective 1/1/2077. (SD1)

Who sponsors HI SB 2751?

IHARA is the primary sponsor of HI SB 2751.

Description

Defines compounded prescription drugs for the purposes of the State's Workers' Compensation Law. Limits dispensing of prescription drugs by physician to 30 days after the industrial injury and requires all prescription drugs to be obtained through the employer's pharmacy benefit manager thereafter. Requires prescription drugs not approved by the Food and Drug Administration (FDA), such as compounds, to be identified as compounds when listed on the treatment plan and when billed, and be supported by a statement of medical necessity documenting the case of medical need for a compound drug over an FDA-approved over-the-counter or prescription drug of similar therapeutic effect. Effective 1/1/2077. (SD1)

Introduced
2026-01-23
Latest action
2026-03-03 — The committee on JDC deferred the measure.
Bill type
bill
Last updated
—

Subjects

Sponsors

  • IHARAprimary

Committees

Not provided by source.

Action timeline

Newest first

  1. 2026-03-03

    The committee on JDC deferred the measure.

    deferral

  2. 2026-02-24

    The committee(s) on JDC will hold a public decision making on 03-03-26 10:15AM; Conference Room 016 & Videoconference.

  3. 2026-02-12

    Reported from LBT/HHS (Stand. Com. Rep. No. 2217) with recommendation of passage on Second Reading, as amended (SD 1) and referral to JDC.

  4. 2026-02-12

    Report adopted; Passed Second Reading, as amended (SD 1) and referred to JDC.

    passage,reading-2,referral-committee

  5. 2026-02-04

    The committee(s) on LBT recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in LBT were as follows: 4 Aye(s): Senator(s) Elefante, Lamosao, Moriwaki, Fevella; Aye(s) with reservations: none ; 0 No(es): none; and 1 Excused: Senator(s) Ihara.

    committee-passage-favorable

  6. 2026-02-04

    The committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS. The votes in HHS were as follows: 5 Aye(s): Senator(s) San Buenaventura, McKelvey, Kanuha, Keohokalole, Fevella; Aye(s) with reservations: none ; 0 No(es): none; and 0 Excused: none.

    committee-passage-favorable

  7. 2026-01-30

    Referred to LBT/HHS, JDC.

    referral-committee

  8. 2026-01-30

    The committee(s) on LBT/HHS has scheduled a public hearing on 02-04-26 1:00PM; Conference Room 225 & Videoconference.

  9. 2026-01-26

    Passed First Reading.

    reading-1

  10. 2026-01-23

    Introduced.

    introduction

Versions

Documents

Votes

  • The committee(s) on HHS recommend(s) that the measure be PASSED, WITH AMENDMENTS.

    2026-02-04 · pass · 5-0

    Member-level votes (5)
    • San Buenaventura: yes
    • McKelvey: yes
    • Kanuha: yes
    • Keohokalole: yes
    • Fevella: yes
  • The committee(s) on LBT recommend(s) that the measure be PASSED, WITH AMENDMENTS.

    2026-02-04 · pass · 4-0

    Member-level votes (5)
    • Elefante: yes
    • Lamosao: yes
    • Moriwaki: yes
    • Fevella: yes
    • Ihara: not voting

Related bills

Official source

Attribution

Data from openstates_bulk_csv, retrieved 2026-07-24T05:20:09.051962Z

Inspect retained evidence for changes recorded after evidence tracking began:

Session-wide evidence can include changes to other bills:

Use this data

Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=HI&identifier=SB 2751. See the API docs or the MCP server for AI assistants.

Known limitations

  • Sponsor party and chamber affiliation are not yet captured by this API.
  • Committee referrals are not yet captured.

See the methodology page for data sources and limitations.